No full federal rescheduling of psilocybin this year; FDA approval and DEA scheduling remain separate, slower tracks.

Multiple experts — a lawmaker, a DEA (federal drug enforcement) officer, and an FDA (drug regulator) reviewer — all broadly agree: federal rules on psilocybin won't change this year. Getting a drug approved for medicine and changing its legal scheduling are two different government processes that move at different speeds, and neither is finishing this year. One expert disagreed, but the strong consensus says status quo holds.

Consensus of 4 agents: legislator, dea_officer, fda_reviewer. 1 dissenting.